Tetrabamate Explained

Type:	combo
Component1:	Febarbamate
Class1:	Carbamate, barbiturate
Component2:	Difebarbamate
Class2:	Carbamate, barbiturate
Component3:	Phenobarbital
Class3:	Barbiturate
Chembl:	1909287

Tetrabamate (Atrium, G Tril, Sevrium) is a combination drug formulation of febarbamate, difebarbamate, and phenobarbital which was marketed in France and Spain and was used to treat anxiety and alcohol withdrawal-associated muscle tremors, agitation, and depression.^{[1] [2] [3] [4]} It was largely, but not completely discontinued on April 4, 1997, after over 30 years of use due to reports of hepatitis and acute liver failure.^{[5] [6]} The decision to restrict the use of the drug had been long-awaited.

Notes and References

1. Book: Index nominum 2000: international drug directory . 26 November 2011 . 2000 . Taylor & Francis US . 978-3-88763-075-1 . 333 & 427.
2. Book: Chitturi S, Farrell GC . Drug-Induced Liver Disease . Schiff ER, Maddrey WC, Sorrell MF . Schiff's Diseases of the Liver . https://books.google.com/books?id=HsxFSx_B4sUC&pg=PT2276 . 26 November 2011 . 19 October 2011 . 703–783 . John Wiley and Sons . 978-1-119-95048-6 . 10.1002/9781119950509.ch27 .
3. Binder D, Jost R, Flury R, Salomon F . [Acute liver failure following tetrabamate] . de . Schweizerische Medizinische Wochenschrift . 125 . 19 . 965–969 . May 1995 . 7761807 .
4. Book: Consolidated list of products whose consumption and/or sale have been banned, withdrawn, severely restricted or not approved by governments . 26 November 2011 . 2003 . United Nations Publications . 978-92-1-130230-1 . 259 .
5. Horsmans Y, Lannes D, Pessayre D, Larrey D . Possible association between poor metabolism of mephenytoin and hepatotoxicity caused by Atrium, a fixed combination preparation containing phenobarbital, febarbamate and difebarbamate . Journal of Hepatology . 21 . 6 . 1075–1079 . December 1994 . 7699230 . 10.1016/s0168-8278(05)80620-8 .
6. Severe hepatitis due to Atrium . Prescrire International . 10 . 55 . 150 . October 2001 . 11824432 .